These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24467886)

  • 1. Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer.
    Morandi A; Isacke CM
    Breast Cancer Res; 2014 Jan; 16(1):301. PubMed ID: 24467886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.
    Gattelli A; Nalvarte I; Boulay A; Roloff TC; Schreiber M; Carragher N; Macleod KK; Schlederer M; Lienhard S; Kenner L; Torres-Arzayus MI; Hynes NE
    EMBO Mol Med; 2013 Sep; 5(9):1335-50. PubMed ID: 23868506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
    Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
    Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
    Wang C; Mayer JA; Mazumdar A; Brown PH
    Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
    Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET in breast cancer: functional and therapeutic implications.
    Morandi A; Plaza-Menacho I; Isacke CM
    Trends Mol Med; 2011 Mar; 17(3):149-57. PubMed ID: 21251878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
    Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
    Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ER-positive breast cancer cells are poised for RET-mediated endocrine resistance.
    Horibata S; Rice EJ; Mukai C; Marks BA; Sams K; Zheng H; Anguish LJ; Coonrod SA; Danko CG
    PLoS One; 2018; 13(4):e0194023. PubMed ID: 29608602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
    Kakati RT; Kim H; Whitman A; Spanheimer PM
    Breast Cancer Res Treat; 2023 Jun; 199(3):589-601. PubMed ID: 37061618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
    Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
    Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.
    Gattelli A; Hynes NE; Schor IE; Vallone SA
    J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):13-26. PubMed ID: 32080788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
    Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
    Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
    Mechera R; Soysal SD; Piscuoglio S; Ng CKY; Zeindler J; Mujagic E; Däster S; Glauser P; Hoffmann H; Kilic E; Droeser RA; Weber WP; Muenst S
    BMC Cancer; 2019 Jan; 19(1):41. PubMed ID: 30621641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.
    Spanheimer PM; Woodfield GW; Cyr AR; Kulak MV; White-Baer LS; Bair TB; Weigel RJ
    Ann Surg Oncol; 2013 Jul; 20(7):2204-12. PubMed ID: 22878616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
    Lazaro G; Smith C; Goddard L; Jordan N; McClelland R; Barrett-Lee P; Nicholson RI; Hiscox S
    Endocr Relat Cancer; 2013 Oct; 20(5):691-704. PubMed ID: 23900794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src-dependent autophagic degradation of Ret in FAK-signalling-defective cancer cells.
    Sandilands E; Serrels B; Wilkinson S; Frame MC
    EMBO Rep; 2012 Aug; 13(8):733-40. PubMed ID: 22732841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
    Boulay A; Breuleux M; Stephan C; Fux C; Brisken C; Fiche M; Wartmann M; Stumm M; Lane HA; Hynes NE
    Cancer Res; 2008 May; 68(10):3743-51. PubMed ID: 18483257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
    Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
    Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells.
    Fan TC; Yeo HL; Hsu HM; Yu JC; Ho MY; Lin WD; Chang NC; Yu J; Yu AL
    Cancer Lett; 2018 Oct; 434():184-195. PubMed ID: 30040982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.
    Griseri P; Garrone O; Lo Sardo A; Monteverde M; Rusmini M; Tonissi F; Merlano M; Bruzzi P; Lo Nigro C; Ceccherini I
    Oncotarget; 2016 May; 7(18):26465-79. PubMed ID: 27034161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.